GlobeNewswire: Summit Therapeutics plc Contains the last 10 of 586 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T17:25:13ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/05/18/2231419/0/en/Summit-Therapeutics-Announces-Preclinical-Candidate-and-Associated-CARB-X-Funding-Support-for-the-Treatment-of-Infections-Caused-by-Carbapenem-Resistant-Enterobacteriaceae-a-CDC-Ur.html?f=22&fvtc=4&fvtv=25328Summit Therapeutics Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae, a CDC Urgent Threat and WHO Critical Priority2021-05-18T11:00:00Z<![CDATA[Cambridge, MA, May 18, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today that it has selected a new preclinical candidate, SMT026738 (“SMT-738”), for development in the fight against multidrug resistant infections, specifically carbapenem-resistant Enterobacteriaceae (CRE) infections. Simultaneously, Summit has received an award from CARB-X to progress this candidate through preclinical development and Phase 1a clinical trials. The award commits initial funding of up to $4.1 million, with the possibility of up to another $3.7 million based on the achievement of future milestones.]]>https://www.globenewswire.com/news-release/2021/05/17/2230633/0/en/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-First-Quarter-Ended-March-31-2021.html?f=22&fvtc=4&fvtv=25328Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 20212021-05-17T12:00:00Z<![CDATA[Cambridge, MA, May 17, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2021.]]>https://www.globenewswire.com/news-release/2021/05/12/2228606/0/en/Summit-Therapeutics-Announces-Closing-of-75-Million-Rights-Offering.html?f=22&fvtc=4&fvtv=25328Summit Therapeutics Announces Closing of $75 Million Rights Offering2021-05-12T18:59:00Z<![CDATA[Cambridge, MA, May 12, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today the successful closing of its fully subscribed rights offering and the associated results.]]>https://www.globenewswire.com/news-release/2021/05/06/2224445/0/en/Summit-Therapeutics-Publishes-Scientific-Updates-to-Corporate-Website.html?f=22&fvtc=4&fvtv=25328Summit Therapeutics Publishes Scientific Updates to Corporate Website2021-05-06T12:00:00Z<![CDATA[Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that we have updated the scientific and related content on our corporate website with respect to our investigational drug, ridinilazole, which is currently enrolling patients in its Phase 3 clinical trials.]]>https://www.globenewswire.com/news-release/2021/05/05/2223740/0/en/Summit-Therapeutics-Rights-Offering-Nearing-Expiration-Date-Robert-W-Duggan-Declares-Intention-to-Fully-Oversubscribe-in-the-Rights-Offering.html?f=22&fvtc=4&fvtv=25328Summit Therapeutics’ Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering2021-05-05T16:47:10Z<![CDATA[Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Daylight Time on May 10, 2021 (the “Expiration Date”). Importantly, for stockholders whose shares of our common stock are held in a brokerage account or are otherwise not registered directly with the Company, the deadline to exercise their subscription rights with their respective brokerage firms may be as soon as today, Wednesday May 5. Examples of brokerage firms with whom shareholders may have accounts include E*TRADE, Charles Schwab, and other personal, financial, or online brokers. Information regarding specific broker-related deadlines can be obtained directly from the broker.]]>https://www.globenewswire.com/news-release/2021/04/21/2214111/0/en/Summit-Therapeutics-Announces-Commencement-of-Rights-Offering.html?f=22&fvtc=4&fvtv=25328Summit Therapeutics Announces Commencement of Rights Offering2021-04-21T12:04:38Z<![CDATA[Summit Therapeutics Inc.(‘Summit’ or the ‘Company’)]]>https://www.globenewswire.com/news-release/2021/03/26/2199960/0/en/Summit-Therapeutics-Announces-Rights-Offering.html?f=22&fvtc=4&fvtv=25328Summit Therapeutics Announces Rights Offering2021-03-26T11:00:00Z<![CDATA[Cambridge, MA, March 26, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of the Company’s common stock, par value $0.01 (the “Common Stock”) as of the close of business on April 9, 2021. The Company intends to distribute to all holders of Common Stock as of the record date non-transferable subscription rights to purchase shares of Common Stock at a price per share equal to the lesser of (i) $5.24 per share, the closing price of the Common Stock on March 24, 2021, or (ii) the volume weighted-average price of the Common Stock for the ten consecutive trading days through and including the expiration date of the offering, currently contemplated to be May 4, 2021. Assuming that the rights offering is fully subscribed, the Company will receive gross proceeds of up to $75 million, less expenses related to the rights offering.]]>https://www.globenewswire.com/news-release/2021/03/17/2194397/0/en/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Fourth-Quarter-and-Year-Ended-December-31-2020.html?f=22&fvtc=4&fvtv=25328Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 20202021-03-17T11:00:00Z<![CDATA[Summit Therapeutics Inc.(‘Summit’ or the ‘Company’)]]>https://www.globenewswire.com/news-release/2020/11/23/2131641/0/en/Summit-Therapeutics-Appoints-Dr-Mahkam-Maky-Zanganeh-as-Chief-Operating-Officer.html?f=22&fvtc=4&fvtv=25328Summit Therapeutics Appoints Dr. Mahkam (“Maky”) Zanganeh as Chief Operating Officer2020-11-23T12:00:00Z<![CDATA[Summit Therapeutics Inc.(‘Summit,’ the ‘Company,’ or the ‘Group’)]]>https://www.globenewswire.com/news-release/2020/11/16/2127753/0/en/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Third-Quarter-and-Nine-Months-Ended-September-30-2020.html?f=22&fvtc=4&fvtv=25328Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 20202020-11-16T21:05:00Z<![CDATA[Summit Therapeutics Inc.(‘Summit’, the ‘Company’ or the ‘Group’)]]>